Article: Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines

Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due to the rapidly evolving pandemic, such adjustments often need to be introduced before full efficacy data are available. As demonstrated in other areas of drug development, quantitative systems pharmacology (QSP) is well placed to guide such extrapolation in a rational and timely manner. Here, we propose for the first time how QSP can be applied in the context of COVID-19 vaccine development.

Citing Articles

Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance.

Urdy S, Hanke M, Toledo A, Ratto N, Jacob E, Peyronnet E Sci Rep. 2024; 14(1):27190.

PMID: 39516205 PMC: 11549341. DOI: 10.1038/s41598-024-72716-1.

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data.

Moore M, Zhu Y, Hirsch I, White T, Reiner R, Barber R Epidemics. 2024; 47:100768.

PMID: 38643547 PMC: 11257040. DOI: 10.1016/j.epidem.2024.100768.

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.

Dari A, Jacqmin P, Iwaki Y, Neyens M, Le Gars M, Sadoff J CPT Pharmacometrics Syst Pharmacol. 2023; 12(10):1485-1498.

PMID: 37715342 PMC: 10583247. DOI: 10.1002/psp4.13025.

QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation.

Matthews R, Hollinshead D, Morrison D, van der Graaf P, Kierzek A CPT Pharmacometrics Syst Pharmacol. 2023; 12(7):889-903.

PMID: 37452454 PMC: 10349184. DOI: 10.1002/psp4.12972.

Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.

Rhodes S, Smith N, Evans T, White R Vaccine. 2022; 40(49):7032-7041.

PMID: 36272876 PMC: 9574467. DOI: 10.1016/j.vaccine.2022.10.012.

References

1.

Kierzek A, Hickling T, Figueroa I, Kalvass J, Nijsen M, Mohan K . A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins. CPT Pharmacometrics Syst Pharmacol. 2019; 8(11):773-776. PMC: 6875700. DOI: 10.1002/psp4.12465. View

2.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

3.

Chen X, Hickling T, Vicini P . A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e134. PMC: 4211264. DOI: 10.1038/psp.2014.31. View

4.

Allen R, Rieger T, Musante C . Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol. 2016; 5(3):140-6. PMC: 4809626. DOI: 10.1002/psp4.12063. View

5.

Chelliah V, Lazarou G, Bhatnagar S, Gibbs J, Nijsen M, Ray A . Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm. Clin Pharmacol Ther. 2020; 109(3):605-618. PMC: 7983940. DOI: 10.1002/cpt.1987. View

6.

Ledford H . Could mixing COVID vaccines boost immune response?. Nature. 2021; 590(7846):375-376. DOI: 10.1038/d41586-021-00315-5. View

7.

Walsh E, Frenck Jr R, Falsey A, Kitchin N, Absalon J, Gurtman A . Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25):2439-2450. PMC: 7583697. DOI: 10.1056/NEJMoa2027906. View

8.

Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M . Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2020; 384(1):80-82. PMC: 7727324. DOI: 10.1056/NEJMc2032195. View

9.

Iacobucci G, Mahase E . Covid-19 vaccination: What's the evidence for extending the dosing interval?. BMJ. 2021; 372:n18. DOI: 10.1136/bmj.n18. View

10.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

11.

Zineh I . Quantitative Systems Pharmacology: A Regulatory Perspective on Translation. CPT Pharmacometrics Syst Pharmacol. 2019; 8(6):336-339. PMC: 6618141. DOI: 10.1002/psp4.12403. View

Application of Quantitative Systems Pharmacology to Guide the Optimal Dosing of COVID-19 Vaccines